SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?


To: Cogito Ergo Sum who wrote (174675)7/12/2021 3:52:10 PM
From: sense1 Recommendation

Recommended By
Maurice Winn

  Read Replies (1) | Respond to of 217749
 
lock and key ... no more complicated than that..

Well, locks and keys... the garage door always has its own... and a whole key ring full of keys... as many locks to be managed... for different things... with a couple of master keys for particular sets of locks...

And, like our own, the keys don't operate themselves... but have to have a meat bag operating them... so not just about the key... but about the nature of the janitor tasked to carry them...

So, a bit more complexity than a casual look might suggest...

Including that most keys open a range of different locks... more or less well... while quite a few have variable functions... working one way if X is true... and working the opposite way if Y is true... while X and Y can be variably present... so functions, and rate of function, often depending on concentrations of other things... homeostasis as a concept important to understand...

And most locks are opened by a range of keys, more or less well...

The overlaps in the lack of specificity is a huge issue...

That's what most drug discovery is about... finding keys that are specific enough to a particular lock, only... with high enough function in addressing that one, only, at low enough concentrations, that others aren't impacted... along with a proper ride to get to the scene of the lock... and a get-away plan that doesn't involve long vacations, detours or gunfights on the way out...



To: Cogito Ergo Sum who wrote (174675)7/12/2021 8:24:32 PM
From: TobagoJack  Read Replies (4) | Respond to of 217749
 
the matter is complicated and I remain agnostic

The Italian woman, who tested positive for Covid-19 antibodies in a blood test taken in June 2020, months after her illness, remains one of the most intriguing early cases, scientists say. Dr. Gianotti, the University of Milan dermatologist, took a skin sample from the 25-year-old woman at Policlinico hospital on Nov. 10, 2019. The woman was suffering from a rash, a symptom that the U.S. Centers for Disease Control and Prevention says appears in some Covid-19 patients.

wsj.com

Clues to Covid-19’s Origins Include Anonymous Skin Sample in Italy

Case of Milan woman sickened in late 2019 has intrigued global researchers

By , and
July 12, 2021 9:00 am ET


Giovanni Fellegara, seated, Raffaele Gianotti and Massimo Barberis, in gray sweater, in Milan in February. The details of a woman featured in research they published have been lost.Photo: Emanuele Cremaschi/Getty Images

MILAN—In the quest to understand how the Covid-19 pandemic began, one persistent mystery is an Italian woman who researchers say they can no longer find.

Members of a World Health Organization-led team studying the origins of the virus want to investigate the case of a 25-year-old Milan resident who in November 2019 visited a hospital with a sore throat and skin lesions: symptoms of a disease that wouldn’t be discovered in the city of Wuhan in China for another month. She left behind a skin sample, smaller than a dime, that in two tests conducted more than six months later yielded traces of the Covid-19 virus, according to research published in January by the British Journal of Dermatology.

Additional studies of the woman’s case, scientists say, could help determine how long the virus was circulating in China and elsewhere before a cluster of cases erupted at Wuhan’s Huanan seafood market in December 2019. The Covid-19-positive skin sample, sitting in wax in a researcher’s office in Milan, is an example of the scattered clues about the pandemic’s early days that the WHO-led investigation is pursuing outside of China, where the pandemic began.

“You cannot ignore it,” said Dutch virologist Marion Koopmans, a member of the WHO-led team, referring to the Italian case in an April interview. She said the case offered enough evidence to merit broader investigation into whether the virus had spread to Italy by November 2019.


Marion Koopmans, a member of the WHO-led team looking into the origins of Covid-19, said the case of the Italian woman merits further investigation.Photo: hector retamal/Agence France-Presse/Getty Images
The problem, researchers say, is that none of them know who or where she is. Milan’s Policlinico hospital and the University of Milan, which oversaw her case, said they don’t have her details. Raffaele Gianotti, the dermatologist who treated her, died in March, days before the WHO-led team asked for more research into his patient. Covid-19 didn’t cause his death, said his wife, Roberta Massobrio.

The WHO-led team has recommended looking in other countries for possible Covid-19 cases that predate the first confirmed case, a Wuhan resident with the surname Chen who fell sick in early December 2019. Beijing has said its part of the WHO-led investigation is complete, and has defied calls from the U.S., the European Union and the WHO to pursue further studies.

Examining earlier suspected cases could help establish a timeline of the virus’s early spread, scientists say. If genetic material can be recovered, they say it could help them determine how the earliest cases might be related.


The WHO-led team looking for clues of Covid-19’s origins visited Wuhan in February.Photo: hector retamal/Agence France-Presse/Getty Images
The WHO-led team has called for blood banks in countries including Italy to test samples from late 2019 for antibodies to the virus. Several studies have yielded evidence that people were infected before the first Covid-19 cases were reported in their areas.

But searching for more cases that predate the Wuhan cluster in a haystack of global blood samples is laborious, researchers say. “You have to screen a huge number of samples,” said Giuseppe Remuzzi, director of the Mario Negri Institute for Pharmacological Research in Milan. “I don’t think it’s really feasible.”

The Italian woman, who tested positive for Covid-19 antibodies in a blood test taken in June 2020, months after her illness, remains one of the most intriguing early cases, scientists say. Dr. Gianotti, the University of Milan dermatologist, took a skin sample from the 25-year-old woman at Policlinico hospital on Nov. 10, 2019. The woman was suffering from a rash, a symptom that the U.S. Centers for Disease Control and Prevention says appears in some Covid-19 patients.

Related Video

Wuhan, Former Pandemic Center, Emerges as Tourist Hot Spot

0:00 / 4:52

3:35

Wuhan, Former Pandemic Center, Emerges as Tourist Hot Spot

Wuhan, the city at the center of the coronavirus pandemic, had the most tourists of any Chinese city during a public holiday in October. Wuhan is overcoming its pandemic past and benefiting from its hero-city status to become a top travel destination. Photo: Getty Images
Months later, when the pandemic hit Italy in early 2020, Dr. Gianotti, cloistered at home under lockdown, went back through archived skin samples looking for unidentified Covid-19 cases. In the one-fifth-of-an-inch wide sample from the 25-year-old, he found what he believed to be evidence that Covid-19 was spreading abroad weeks before it was identified in Wuhan.

Two tests on the sample found the presence of the virus’s spike protein and nucleocapsid, or protein shell. The sample was too degraded to yield enough RNA to genetically sequence the virus, which would have offered a third and more definitive layer of confirmation and possibly enabled researchers to compare it with cases in China.


The coffin of a Covid-19 victim at Policlinico hospital in Milan in November.Photo: paolo salmoirago/Shutterstock
“I was disappointed for only one thing,” said Massimo Barberis, a co-author on Dr. Gianotti’s research and the director of Milan’s European Institute of Oncology’s histopathological and molecular diagnostic clinic. “That we cannot confirm it with another, third technique.”

Between the patient’s illness at the end of 2019 and the antibody test in mid-2020, the Covid-19 pandemic had swept across northern Italy, which could have exposed the patient to an asymptomatic infection after her illness, Dr. Barberis and other scientists said.

But the tests to detect SARS-CoV-2 RNA that Dr. Gianotti conducted on the skin sample make a compelling case for the presence of Covid-19, said Ian Lipkin, an infectious-disease specialist at Columbia University. The WHO-led team on March 30 recommended further studies into the suspected case, among others from late 2019.

Three days earlier, Dr. Gianotti had died suddenly at 61 years old. The researchers who co-wrote his paper including Dr. Barberis said they don’t know the name, contact details or residence of the woman who yielded the skin sample.

The University of Milan has no record of the patient, said a spokeswoman and other officials there. A spokeswoman for Policlinico hospital said it didn’t have a file on the woman.

As the pandemic fades in Europe, Dr. Barberis said he believes researchers have lost enthusiasm for figuring out how it began: “People are not interested.”

Investigating the Origin of Covid-19
Related coverage, selected by the editors

Write to Eric Sylvers at eric.sylvers@wsj.com, Drew Hinshaw at drew.hinshaw@wsj.com and Betsy McKay at betsy.mckay+1@wsj.com